1.	Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MORAb003-004, NCT00849667
2.	Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MORAb-003-002, NCT00318370
3.	An Open Label Extension Study of the Efficacy of MORAb-003 Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MORAb-003-002A, NCT01018563
4.	A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MORAb-003-009, NCT01218516
5.	Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MORAb-003-001, NCT00428766
6.	Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MORAb-003-005, NCT01004380
7.	A Study of MORAb-003 in Patients With Solid Tumor Phase: Phase I Type: Treatment Status: Closed Age: 20 to 79 Sponsor: Pharmaceutical / Industry Protocol IDs: MORAB-003-J081-102, NCT01049061